General Information of the Protein
Protein ID |
PT01403
|
||||
---|---|---|---|---|---|
Protein Name |
Cyclin-dependent kinase 7
|
||||
Secondarily Protein Name |
39 kDa protein kinase
CDK-activating kinase 1
Cell division protein kinase 7
Serine/threonine-protein kinase 1
TFIIH basal transcription factor complex kinase subunit
|
||||
Gene Name |
CDK7
|
||||
Secondarily Gene Name |
CAK
CAK1
CDKN7
MO15
STK1
|
||||
Sequence |
MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Enzyme
>
Kinase
>
Protein Kinase
>
CMGC protein kinase group
>
CMGC protein kinase CDK family
>
CMGC protein kinase CDK7 subfamily
|
||||
Function |
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts (PubMed:9852112). Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Nucleus
Cytoplasm
Cytoplasm
Perinuclear region
|
Clinical Information about the Protein
Target 1 ( Cyclin-dependent kinase 7 (CDK7) )
Target Type | Clinical trial Target | ||||
---|---|---|---|---|---|
Disease | 5 Target-related Diseases | 5 | |||
1 | Non-small-cell lung cancer [ICD-11: 2C25.Y] | ||||
2 | Breast cancer [ICD-11: 2C60-2C65] | ||||
3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||
4 | Advanced solid tumour [ICD-11: 2A00-2F9Z] | ||||
5 | Nasopharyngeal carcinoma [ICD-11: 2B6B] | ||||
Clinical Trial Drug(s) | 5 Clinical Trial Drugs | 5 | |||
1 | R-roscovitine | Phase 2 | |||
2 | Samuraciclib | Phase 1/2 | |||
3 | LY3405105 | Phase 1 | |||
4 | SNS-032 | Phase 1 | |||
5 | SY-1365 | Phase 1 | |||
Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
1 | R547 | Discontinued in Phase 1 | |||
Investigative Drug(s) | 1 Investigative Drug | 1 | |||
1 | THZ1 | Investigative |